S&P 500   3,149.02 (+1.01%)
DOW   28,013.55 (+1.21%)
QQQ   204.84 (+1.19%)
AAPL   271.00 (+2.04%)
FB   200.60 (+0.62%)
MSFT   151.30 (+0.91%)
GOOGL   1,337.62 (+1.42%)
AMZN   1,749.71 (-0.62%)
CGC   18.59 (-0.05%)
NVDA   212.20 (+1.33%)
MU   47.95 (+2.85%)
T   38.32 (+0.31%)
AMD   39.61 (-0.20%)
ACB   2.42 (-0.82%)
BAC   33.78 (+2.05%)
GILD   67.15 (+0.60%)
S&P 500   3,149.02 (+1.01%)
DOW   28,013.55 (+1.21%)
QQQ   204.84 (+1.19%)
AAPL   271.00 (+2.04%)
FB   200.60 (+0.62%)
MSFT   151.30 (+0.91%)
GOOGL   1,337.62 (+1.42%)
AMZN   1,749.71 (-0.62%)
CGC   18.59 (-0.05%)
NVDA   212.20 (+1.33%)
MU   47.95 (+2.85%)
T   38.32 (+0.31%)
AMD   39.61 (-0.20%)
ACB   2.42 (-0.82%)
BAC   33.78 (+2.05%)
GILD   67.15 (+0.60%)
S&P 500   3,149.02 (+1.01%)
DOW   28,013.55 (+1.21%)
QQQ   204.84 (+1.19%)
AAPL   271.00 (+2.04%)
FB   200.60 (+0.62%)
MSFT   151.30 (+0.91%)
GOOGL   1,337.62 (+1.42%)
AMZN   1,749.71 (-0.62%)
CGC   18.59 (-0.05%)
NVDA   212.20 (+1.33%)
MU   47.95 (+2.85%)
T   38.32 (+0.31%)
AMD   39.61 (-0.20%)
ACB   2.42 (-0.82%)
BAC   33.78 (+2.05%)
GILD   67.15 (+0.60%)
S&P 500   3,149.02 (+1.01%)
DOW   28,013.55 (+1.21%)
QQQ   204.84 (+1.19%)
AAPL   271.00 (+2.04%)
FB   200.60 (+0.62%)
MSFT   151.30 (+0.91%)
GOOGL   1,337.62 (+1.42%)
AMZN   1,749.71 (-0.62%)
CGC   18.59 (-0.05%)
NVDA   212.20 (+1.33%)
MU   47.95 (+2.85%)
T   38.32 (+0.31%)
AMD   39.61 (-0.20%)
ACB   2.42 (-0.82%)
BAC   33.78 (+2.05%)
GILD   67.15 (+0.60%)
Log in

OTCMKTS:GTBP - GT Biopharma Stock Price, Forecast & News

$0.13
+0.01 (+8.70 %)
(As of 12/6/2019 12:38 PM ET)
Today's Range
$0.12
Now: $0.13
$0.13
50-Day Range
$0.12
MA: $0.16
$0.24
52-Week Range
$0.11
Now: $0.13
$1.00
Volume75,538 shs
Average Volume133,382 shs
Market Capitalization$8.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.45
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GTBP
Previous SymbolOTCMKTS:OXISD
CUSIPN/A
CIKN/A
Phone800-304-9888

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.24 per share

Profitability

Net Income$-259,190,000.00

Miscellaneous

Employees3
Market Cap$8.10 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive GTBP News and Ratings via Email

Sign-up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.


GT Biopharma (OTCMKTS:GTBP) Frequently Asked Questions

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

How were GT Biopharma's earnings last quarter?

GT Biopharma Inc (OTCMKTS:GTBP) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.43) EPS for the quarter. View GT Biopharma's Earnings History.

When is GT Biopharma's next earnings date?

GT Biopharma is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for GT Biopharma.

Has GT Biopharma been receiving favorable news coverage?

News articles about GTBP stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GT Biopharma earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for GT Biopharma.

Who are some of GT Biopharma's key competitors?

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), Canopy Growth (WEED), Canopy Growth (CGC), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), PotNetwork (POTN), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH) and American Cannabis (AMMJ).

Who are GT Biopharma's key executives?

GT Biopharma's management team includes the folowing people:
  • Mr. Anthony J. Cataldo, Chairman of Directors, CEO & Pres (Age 67)
  • Mr. Steven W. Weldon, CFO, Principal Accounting Officer & Director (Age 43)

How do I buy shares of GT Biopharma?

Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $0.13.

How big of a company is GT Biopharma?

GT Biopharma has a market capitalization of $8.10 million. GT Biopharma employs 3 workers across the globe.View Additional Information About GT Biopharma.

What is GT Biopharma's official website?

The official website for GT Biopharma is http://www.gtbiopharma.com/.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at 800-304-9888 or via email at [email protected]


MarketBeat Community Rating for GT Biopharma (OTCMKTS GTBP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about GT Biopharma and other stocks. Vote "Outperform" if you believe GTBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel